Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials

Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout

(2021) Tomohiko Ishikawa et al.   EXPERT OPINION ON PHARMACOTHERAPY

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout

(2020) Tatsuo Hosoya et al.   Clinical and Experimental Nephrology

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study

(2020) Tatsuo Hosoya et al.   Clinical and Experimental Nephrology

Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor

(2019) Tetsuya Taniguchi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)

(2019) Satoshi Umemura et al.   HYPERTENSION RESEARCH

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study

(2019) Tatsuo Hosoya et al.   Clinical and Experimental Nephrology

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study

(2019) Tatsuo Hosoya et al.   Clinical and Experimental Nephrology

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout

(2019) Tatsuo Hosoya et al.   Clinical and Experimental Nephrology

Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation

(2018) Richard J. Johnson et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study

(2017) Lhanoo Gunawardhana et al.   Journal of the American Heart Association

Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia

(2016) Yuko Ohta et al.   HYPERTENSION RESEARCH

Drug-induced hyperuricaemia and gout

(2016) C. Ben Salem et al.   RHEUMATOLOGY

Serum uric acid and the incidence of CKD and hypertension

(2015) Satoru Kuriyama et al.   Clinical and Experimental Nephrology

Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study

(2015) Shigemasa Tani et al.   CLINICAL DRUG INVESTIGATION

Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension

(2014) Masanari Kuwabara et al.   HYPERTENSION RESEARCH

Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study

(2013) Yayoi Nishida et al.   Cardiovascular Diabetology

Japanese Guideline for the Management of Hyperuricemia and Gout: Second Edition

(2011) Hisashi Yamanaka   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk

(2010) M. Goicoechea et al.   Clinical Journal of the American Society of Nephrology

Human Sodium Phosphate Transporter 4 (hNPT4/SLC17A3) as a Common Renal Secretory Pathway for Drugs and Urate

(2010) Promsuk Jutabha et al.   JOURNAL OF BIOLOGICAL CHEMISTRY